Tiêu đề tltk.pdf ✅

126 20. Musil, I., et al. (2010), Enterobacter cloacae infection of an expanded polytetrafluoroethylene femoral-popliteal bypass graft: a case report. J Med Case Rep, 4: p. 131. 21. Sanders, W.E. and C.C. Sanders (1997), Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev, 10(2): p. 220-241. 22. Lee, M.K., et al. (2014), Carbapenem-Resistant Enterobacter cloacae Isolates Producing KPC-3, North Dakota, USA. Emerging Infectious Disease journal, 20(9): p. 1583. 23. Rozwandowicz, M., et al. (2018), Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 73(5): p. 1121-1137. 24. Gillings, M., et al. (2008), The evolution of class 1 integrons and the rise of antibiotic resistance. J Bacteriol, 190(14): p. 5095-5100. 25. Eliopoulos, G.M., S.E. Cosgrove, and Y. Carmeli (2003), The Impact of Antimicrobial Resistance on Health and Economic Outcomes. Clinical Infectious Diseases, 36(11): p. 1433-1437. 26. Giedraitienė, A., et al. (2011), Antibiotic resistance mechanisms of clinically important bacteria. Medicina (Kaunas), 47(3): p. 137-146. 27. Levy, S.B. and B. Marshall (2004), Antibacterial resistance worldwide: causes, challenges and responses. Nat Med, 10(12 Suppl): p. S122-129. 28. Cag, Y., et al. (2016), Resistance mechanisms. Ann Transl Med, 4(17): p. 326. 29. Delcour, A.H. (2009), Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta, 1794(5): p. 808-816. 30. Dolejska, M., et al. (2013), Complete sequencing of an IncHI1 plasmid encoding the carbapenemase NDM-1, the ArmA 16S RNA methylase and a resistance-nodulation-cell division/multidrug efflux pump. J Antimicrob Chemother, 68(1): p. 34-39. 31. Silvestri, L. and H.K. van Saene (2010), Hospital-acquired infections due to gram-negative bacteria. N Engl J Med, 363(15): p. 1482; author reply 1483-1484. 32. Jian, Z., et al. (2021), Antibiotic resistance genes in bacteria: Occurrence, spread, and control. J Basic Microbiol, 61(12): p. 1049-1070. 33. Graham, D.W., et al. (1987), Inhibition of the mammalian beta-lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted-propenoic acids. J Med Chem, 30(6): p. 1074-1090. 34. Birnbaum, J., et al. (1985), Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med, 78(6a): p. 3-21. 35. Schwaber, M.J. and Y. Carmeli (2008), Carbapenem-resistant Enterobacteriaceae: a potential threat. Jama, 300(24): p. 2911-2913. 36. Bassetti, M., et al. (2009), Current status of newer carbapenems. Curr Med Chem, 16(5): p. 564-575. 37. Martínez-Martínez, L. (2008), Extended-spectrum beta-lactamases and the permeability barrier. Clin Microbiol Infect, 14 Suppl 1: p. 82-89. 38. Hashizume, T., et al. (1984), Studies on the mechanism of action of imipenem (N- formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. J Antibiot (Tokyo), 37(4): p. 394-400. 39. van Dam, V., N. Olrichs, and E. Breukink (2009), Specific labeling of peptidoglycan precursors as a tool for bacterial cell wall studies. Chembiochem, 10(4): p. 617-624. 40. Oliver, A., et al. (2004), Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother, 48(11): p. 4226-4233. 41. Mandell, L. (2009), Doripenem: a new carbapenem in the treatment of nosocomial infection. Clin Infect Dis, 49 Suppl 1: p. S1-3.